Novartis Gets EU Approval For Skin Cancer Treatment Odomzo
August 20 2015 - 3:03AM
Dow Jones News
By Neil MacLucas
ZURICH--European regulators have approved Novartis AG's
(NOVN.VX) Odomzo capsules, providing non-invasive treatment for
patients with a type of skin cancer, the company said Thursday.
Basel-based Novartis said the European Commission approved
Odomzo for treating adults with advanced basal cell carcinoma,
which accounts for more than 80% of non-melanoma skin cancers.
Worldwide incidence of the disease, which causes uncontrolled
growths or lesions on the skin, is increasing by 10% per year due
to the aging population and heightened exposure to ultraviolet
light.
Odomzo has already been approved in the U.S., Australia and
Switzerland and further regulatory applications have been made to
health authorities around the world.
Write to Neil MacLucas at neil.maclucas@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 20, 2015 02:48 ET (06:48 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
